BlueRock Therapeutics develops advanced cellular therapies using a unique cell gene platform that directs cellular differentiation and genetically engineers cells. This technology allows them to create new types of cellular medicines aimed at treating diseases in neurology, cardiology, and immunology. Their products work by transforming cells to target complex medical conditions such as neurodegenerative diseases, heart failure, and immune disorders. Unlike many competitors, BlueRock focuses specifically on these challenging areas and collaborates with healthcare providers, research institutions, and pharmaceutical companies to bring their therapies to market. The company's goal is to advance regenerative medicine through extensive research and development, strategic partnerships, and the commercialization of their therapies once they receive regulatory approval.

Bayer

Versant Ventures

Biotechnology

Healthcare

BlueRock Therapeutics

OpCT-001 is the first iPSC therapy candidate licensed from the strategic research and development alliance that FUJIFILM Cellular Dynamics, Opsis Therapeutics, and BlueRock Therapeutics entered in 2021 to discover and develop off-the-shelf iPSC-derived cell therapies for ocular diseases.

Fujifilm Congratulates BlueRock Therapeutics for Receiving FDA Clearance of its IND Application for its iPSC-derived Cell Therapy Candidate

Since May 2021, BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics have had an R&D alliance to develop allogeneic iPSC-derived cell therapies for ocular diseases.

iPSC Applications in Cell Therapy, Drug Discovery, and Beyond

The U.S. Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to bemdaneprocel, a cell therapy BlueRock Therapeutics, a subsidiary of Bayer, is developing to treat Parkinson's disease.

Cell therapy bemdaneprocel gets FDA RMAT status

Investigational cellular therapy, bemdaneprocel (BRT-DA01), was well tolerated with no major safety issues in all 12 participants in low dose and high dose cohorts through one year.At one-year, exploratory clinical endpoints improved overall, with participants in the high dose cohort showing greater improvement.One year assessment of all participants demonstrated feasibility of transplantation, cell survival, and engraftment.Planning is underway for a Phase II study that is expected to begin enrolling participants in H1 (first half) 2024.BERLIN and CAMBRIDGE, Mass., Aug. 28, 2023 /PRNewswire/ -- Bayer AG and BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned independently operated subsidiary of Bayer AG, announced today details of the positive data from the Phase I clinical trial for bemdaneprocel (BRT-DA01), a stem cell derived investigational therapy for treating Parkinson's disease. The data were presented at the International Congress of Parkinson's Disease and Movement Disorders® in Copenhagen, Denmark.The study met the primary objective of demonstrating safety and tolerability in all 12 participants in the study's low and high dose cohorts, with no serious adverse events (SAEs) reported related to bemdaneprocel through one year. There were two SAEs reported that were unrelated to bemdaneprocel, one seizure attributed to the surgical procedure and one COVID case. Both resolved without sequelae. In addition, 18F-DOPA PET imaging scans demonstrated evidence of cell survival and engraftment in both low and high dose cohorts

Bluerock'S Phase I Study With Bemdaneprocel In Patients With Parkinson'S Disease Meets Primary Endpoint

BlueRock and bit.bio link to develop regulatory T cell-based therapies.

BlueRock and bit.bio link to develop regulatory T cell-based therapies

Research collaboration leverages bit.bio's machine learning-powered discovery platform to identify transcription factor (TF) combinations for reprogramming induced pluripotent stem cells (iPSCs) into Tregs.Agreement includes option for BlueRock to license TF combinations emerging from the collaboration as well as an option to license bit.bio's opti-ox™ precision cell programming technology for the manufacture and subsequent development of iPSC-derived Treg cell therapies.bit.bio receives an upfront payment from BlueRock and is eligible to receive milestone payments and royalties on worldwide sales of all therapies resulting from the collaboration.CAMBRIDGE, Mass. and CAMBRIDGE, United Kingdom, Aug. 3, 2023 /PRNewswire/ -- BlueRock Therapeutics LP, a clinical stage cell therapy company and wholly owned, independently operated subsidiary of Bayer AG, and bit.bio, the company coding human cells for novel cures, today announced a collaboration and option agreement for the discovery and manufacture of iPSC-derived regulatory T cells (Tregs) for use in creating therapeutics."Tregs play a crucial role in maintaining balance in the body's immune system and controlling excessive immune reactions," said Stefan Irion, MD, Chief Scientific Officer of BlueRock Therapeutics. "iPSC-derived Treg based therapies have the potential to treat a broad range of autoimmune and inflammatory disorders, and we look forward to collaborating with the bit.bio team to explore how their opti-ox cell programming technology can accelerate our efforts to discover and manufacture Tregs from iPSCs.""We are delighted to partner with the team at BlueRock, who are world-leaders in iPSC-derived cell therapies, and together address the significant unmet needs of these patients." said Mark Kotter, MD PhD, CEO of bit.bio. "Today's announcement marks an important milestone for bit.bio. As well as providing significant financial contributions, our collaboration is a testament to the unique capabilities of bit.bio's team."Under the terms of the agreement, bit.bio will use its machine learning powered discovery platform to identify transcription factor (TF) combinations for reprogramming iPSCs into Tregs

Bluerock Therapeutics And Bit.Bio Announce Collaboration And Option Agreement For The Discovery And Manufacture Of Regulatory T Cell (Treg) Based Therapies

BlueRock Therapeutics and bit.bio announced a research collaboration and option agreement for the discovery and manufacture of iPSC-derived therapeutic regulatory T cells (Tregs).

Cell therapy weekly: BlueRock and bit.bio join forces for iPSC-derived immune solutions

“Parkinsonsnewstoday is on a mission to harness the power of cell therapy with the aim to help people with Parkinson’s disease regain control of their lives by restoring the functions that they have lost to this disease,” Ahmed Enayetallah, MD, PhD, senior vice president and head of development at BlueRock Therapeutics, a wholly owned subsidiary of Bayer, said in a press release.

Cell therapy bemdaneprocel safe in advanced Parkinson’s: Phase 1 trial | Parkinson's News Today

Innovation At The Core Of HealthcareThe pharmaceutical industry has been built on the back of scientific innovation. The first innovators a century ago have turned into large pharmaceutical companies regularly re-inventing themselves.This is because life sciences and medicine have evolved equally fast in the last few generations. In addition, patent protection often expires less than 10-15 years after the commercialization of a new therapy, forcing pharmaceutical companies to constantly invent new products.Thanks to this pressure to constantly innovate, even large companies kept the incentives to stay able to invent regularly life-changing medicine.In this article, we will see some of the best healthcare innovators, in all arrays of medicine, from cancer treatments to vaccines, rare diseases, neurosciences, or metabolic therapies.Top 10 Pharmaceutical Stocks for Healthcare Innovation(These stocks are organized by market capitalization at the time of writing of this article)Johnson & Johnson ( JNJ )The largest pharmaceutical company by revenues in 2022, with $94B. The company operates as a conglomerate of 3 sub-businesses: pharmaceuticals, medical devices, and consumer healthcare (by importance order).It operates no less than 29 products or platforms with more than $1B in annual sales. Non-medical professionals might be more familiar with some of the consumer health products like Listerine, Neutrogena, or Tylenol. Still, more than half of its revenues are from pharmaceuticals, with a focus on 6 therapeutic areas:Immunology.Infectious diseases.NeurosciencesOncologyCardiovascular & metabolism.Pulmonary hypertension.J&J was the second largest pharmaceutical company by R&D investment in 2022 and boasts an impressive lineup:6 new products approved in 2022.20 large MedTech pipeline programs.81 innovation deals.20 new equity investments in 2022.8 licensing agreements in 2022.With its highly diversified activities in consumer health, pharmaceutical, and medical devices, J&J is a good pick for investors looking to bet on pharmaceutical innovation with as little volatility as possible.(You can read more about J&J's innovation strategy from this transcript of a speech given at Sanford C Bernstein Strategic Decisions Conference )Bristol-Myers Squibb Company ( BMY )BMS is a pharmaceutical company with a strong presence in cancer, hematology, immunology, and cardiology.The company is targeting its risk-adjusted sales to grow from $10B-$13B in 2025 to $25+B in 2030, with the growth coming from both currently commercialized blockbuster drugs increasing their market and new therapies

Top 10 Pharmaceutical Stocks For Healthcare Innovation

Big Pharma Is Still AliveThe last few years have seen the healthcare sector changed radically thanks to biotech innovation. The most visible part was mRNA vaccines, but the arrival of gene therapies, cheap genome sequencing, or stem cell therapies are all there to usher in a new era of medical marvels (you can follow the links for deeper coverage of these topics).Most of these innovations have been done by smaller companies, and RD efforts by the biggest pharmaceutical companies have often been not very successful.Nevertheless, the pharmaceutical industry is still dominated by a few giant corporations. Such blue-chip multi-billion dollar companies are not only the historically dominant players, but might as well stay on top for the foreseeable future.Why is that? How is it that even radical innovation might not be a threat to incumbent companies?The Big Pharma Business ModelTo understand how “Big Pharma” can stay on top, we can look at the example of the mRNA vaccines.The innovation itself was very much invented by BioNTech, which took an actually quite old scientific concept and turned it into an entire technology platform.When the pandemic arrived, it was the perfect time for such a “programmable” vaccine to shine. And it did. But BioNTech did not commercialize it themselves. They partnered with Pfizer to handle approval, production, and commercialization as quickly as possible

Top 5 Blue Chip Pharmaceutical Companies (April 2023)

Develops advanced cellular therapies for diseases

BlueRock Therapeutics

Develops advanced cellular therapies for diseases

BlueRock Therapeutics

Develops advanced cellular therapies for diseases

About

Simplify's Take

What believers are saying

What critics are saying

What makes BlueRock Therapeutics unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

BlueRock Therapeutics is Hiring for 0 Jobs on Simplify!